EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP

Xin Cui, Yueming Zhu, Lidan Zeng, Mengyuan Zhang, Amad Uddin, Theresa W Gillespie, Lauren E McCullough, Shaying Zhao, Mylin A Torres, Yong Wan iD

Advanced Science · 2025

DOI: 10.1002/advs.202407494 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Xin Cui und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, 30322, USA. Hauptthemen laut MEDLINE: Obesity, Triple Negative Breast Neoplasms, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Emory University, Winship Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC) in obese patients remains challenging. Recent studies have linked obesity to an increased risk of TNBC and malignancies. Through multiomic analysis and experimental validation, a dysfunctional Eukaryotic Translation Initiation Factor 3 Subunit H (EIF3H)/Yes‐associated protein (YAP) proteolytic axis is identified as a pivotal junction mediating the interplay between cancer‐associated adipocytes and the response to anti‐cancer drugs in TNBC. Mechanistically, cancer‐associated adipocytes drive metabolic reprogramming resulting in an upregulated hexosamine biosynthetic pathway (HBP). This aberrant upregulation of HBP promotes YAP O‐GlcNAcylation and the subsequent recruitment of EIF3H deubiquitinase, which stabilizes YAP, thus promoting tumor growth and chemotherapy resistance. It is found that Retatrutide, an anti‐obesity agent, inhibits HBP and YAP O‐GlcNAcylation leading to increased YAP degradation through the deprivation of EIF3H‐mediated deubiquitylation of YAP. In preclinical models of obese TNBC, Retatrutide downregulates HBP, decreases YAP protein levels, and consequently decreases tumor size and enhances chemotherapy efficacy. This effect is particularly pronounced in obese mice bearing TNBC tumors. Overall, these findings reveal a critical interplay between adipocyte‐mediated metabolic reprogramming and EIF3H‐mediated YAP proteolytic control, offering promising therapeutic strategies to mitigate the adverse effects of obesity on TNBC progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityTriple Negative Breast NeoplasmsAdaptor Proteins, Signal TransducingAnimalsUbiquitinationHumansMiceGlycosylationFemaleYAP-Signaling ProteinsCell Line, TumorTranscription FactorsFatty AcidsPeptides

Stichwörter der Autor:innen

OGTYAPadipocytedeubiquitinaseglycosylationtumorigenesis

Substanzen

YAP-Signaling ProteinsYAP1 protein, humanTranscription FactorsAdaptor Proteins, Signal TransducingretatrutideFatty AcidsPeptides

Autor:innen und Institutionen

  • Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, 30322, USA.
  • Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, 30322, USA.
  • Department of Biochemistry and Molecular Biology, Institute of Bioinformatics, University of Georgia, Athens, GA, 30602, USA.
  • Department of Surgery, Emory University School of Medicine, Atlanta, GA, 30322, USA.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.
  • Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, 30322, USA.

ORCID-Profile: Yong Wan

Förderung

  • NCI NIH HHS
  • Emory University
  • Winship Cancer Institute
  • National Cancer Institute

Zitieren

APA

Cui, X., Zhu, Y., Zeng, L., Zhang, M., Uddin, A., Gillespie, T. W., McCullough, L. E., Zhao, S., Torres, M. A., & Wan, Y. (2025). Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP. Advanced Science. https://doi.org/10.1002/advs.202407494

Vancouver

Cui X, Zhu Y, Zeng L, Zhang M, Uddin A, Gillespie TW, et al. Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP. Advanced Science. 2025. doi:10.1002/advs.202407494

BibTeX
@article{Cui2025,
  author = {Cui, Xin and Zhu, Yueming and Zeng, Lidan and Zhang, Mengyuan and Uddin, Amad and Gillespie, Theresa W and McCullough, Lauren E and Zhao, Shaying and Torres, Mylin A and Wan, Yong},
  title = {Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202407494}
}
Kostenlos starten →